Paruch, K.,Dwyer, M. P.,Alvarez, C.,Brown, C.,Chan, T. Y.,Doll, R. J.,Keertikar, K.,Knutson, C.,McKittrick, B.,Rivera, J.,Rossman, R.,Tucker, G.,Fischmann, T. O.,Hruza, A.,Madison, V.,Nomeir, A. A.,Wang, Y.,Lees, E.,Parry, D.,Sgambellone, N.,Seghezzi, W.,Schultz, L.,Shanahan, F.,Wiswell, D.,Xu, X.,Zhou, Q.,James, R. A.,Paradkar, V. M.,Park, H.,Rokosz, L. R.,Stauffer, T. M.,Guzi, T. J.

2007

November

Bioorg Med Chem Lettbioorg Med Chem Lett

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

Validated

()

17

2222

6220

3

Properly substituted pyrazolo[1,5-a]pyrimidines are potent and selective CDK2 inhibitors. Compound 15j is orally available and showed efficacy in a mouse A2780 xenograft model.Properly substituted pyrazolo[1,5-a]pyrimidines are potent and selective CDK2 inhibitors. Compound 15j is orally available and showed efficacy in a mouse A2780 xenograft model.

0960-894X (Print) 0960-89